Hyperkalemia during spironolactone use in patients with decompensated heart failure;Hiperpotassemia na vigência de espironolactona em pacientes com insuficiência cardíaca descompensada

Arquivos Brasileiros de Cardiologia

Volumn 91, Issue 3, 2008, Pages

  Lima, Marcelo Villaça ^a,b   Ochiai, Marcelo Eidi ^a   Cardoso, Juliano Novaes ^a   Morgado, Paulo César ^a   Munhoz, Robinson Tadeu ^a   Barretto, Antonio Carlos Pereira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Heart failure, congestive; Hyperkalemia; Kidney drug effects; Spirolactone

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL MALEATE; HYDRALAZINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOSORBIDE; LOSARTAN POTASSIUM; NITRATE; POLYSTYRENESULFONATE CALCIUM; POTASSIUM; SORCAL; SPIRONOLACTONE; UNCLASSIFIED DRUG; UREA; VASOACTIVE AGENT;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DECOMPENSATED HEART FAILURE; DRUG EFFECT; DRUG SUBSTITUTION; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERKALEMIA; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POTASSIUM BLOOD LEVEL; RISK FACTOR; SIDE EFFECT; UREA BLOOD LEVEL;

EID: 55949120507     PISSN: 0066782X     EISSN: 16784170     Source Type: Journal    
DOI: 10.1590/S0066-782X2008001500009     Document Type: Article

References (17)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999; 341:709-17.
2. Vereijken TL, Bellersen L, Groenewoud JM, Knubben L, Baltussen L. Risk calculation for hyperkalemia in heart failure patients. Neth J Med. 2007; 65 (6): 208-11.
3. Shah KB, Rao K, Sawyer R, Gottlieb SS. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol. 2005; 46 (5): 845-9.
4. Svensson M, Gustafsson F, Galatius S, Hildebrandt PR, Atar D. Hyperkalaemia and impaired renal function in patients taking spironolactone for congestive heart failure: retrospective study. BMJ. 2003; 327: 1141-2.
5. Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil. J Clin Pharm Ther. 2005; 30 (6): 603-10.
6. Juurlink D, Mamdani M, Lee DS, Kopp A, Austin PC. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351: 543-51.
7. Palmer F. Managing hyperkalemia caused by inhibitors of reninangiotensin-aldosterone system. N Engl J Med. 2004; 351: 585-92.
8. Sociedade Brasileira de Cardiologia. Revisão das II Diretrizes para o diagnóstico e tratamento da insuficiência cardíaca. Arq Bras Cardiol. 2002; 79 (supl 4): 1-30.
9. McMurray J, O'Meara E. Treatment of heart failure with spironolactone - trial and tribulations. N Engl J Med. 2004; 351: 526-8.
10. Saito M, Nakayama D, Takada M, Mirooka K, Yasumura Y. Carvedilol accelerate elevation of serum potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate or candesartan cilexetil. J Clin Pharm Ther. 2006; 31 (6): 535-40.
11. Aggarwal A, Wong J, Campbell DJ. Carvedilol reduces aldosterone release in systolic heart failure. Heart Lung Circ. 2006; 15 (5): 306-9.
12. Hosmer DW, Lemeshow S. Applied logistic regression. New York: Wiley; 1989. p. 106-18.
13. Del Carlo C, Barretto ACP, Oliveira Jr MT, Ochiai ME, Munhoz RT, Canesin MF, et al. Impacto da disfunção renal no prognóstico de pacientes com insuficiência cardíaca avançada [tema livre]. Rev Soc Cardiol Estado de São Paulo. 2007; 17 (supl B): 49.
14. de Silva R, Nikitin N, Witte KK, Rigby AS, Goode K, Bhandari S, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J. 2006; 27: 569-81.
15. Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, et al. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006; 47: 1987-96.
16. Tamirisa KP, Aaronson KD, Koelling TM. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure. Am Heart J. 2004; 148 (6): 971-8.
17. Cruz CS, Cruz AA, Marcílio de Souza CA. Hyperkalaemia in congestive heart failure patients using ACE inhibitors and spironolactone. Nephrol Dial Transplant. 2003; 18 (9): 1814-9.